Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
18F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-Dimensional Transperineal Mapping Biopsy.
Kanoun S, Walker P, Vrigneaud JM, Depardon E, Barbier V, Humbert O, Moulin M, Créhange G, Cormier L, Loffroy R, Brunotte F, Cochet A. Kanoun S, et al. Among authors: brunotte f. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):986-994. doi: 10.1016/j.ijrobp.2016.12.025. Epub 2016 Dec 28. Int J Radiat Oncol Biol Phys. 2017. PMID: 28333020
Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.
Créhange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, Funes de la Vega M, Cormier L, Bonnetain F, Mirjolet C, Brunotte F, Walker PM. Créhange G, et al. Among authors: brunotte f. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1087-94. doi: 10.1016/j.ijrobp.2010.03.007. Epub 2010 Jul 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 20615624
Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.
Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P. Crehange G, et al. Among authors: brunotte f. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e407-13. doi: 10.1016/j.ijrobp.2011.03.008. Epub 2011 May 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 21605949
Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F. Cochet A, et al. Among authors: brunotte f. J Nucl Med. 2012 Apr;53(4):512-20. doi: 10.2967/jnumed.111.096834. Epub 2012 Feb 17. J Nucl Med. 2012. PMID: 22343501 Free article. Clinical Trial.
In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F. Berthet L, et al. Among authors: brunotte f. J Nucl Med. 2013 Aug;54(8):1244-50. doi: 10.2967/jnumed.112.114710. Epub 2013 May 14. J Nucl Med. 2013. PMID: 23674577 Free article.
¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F. Cochet A, et al. Among authors: brunotte f. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37. doi: 10.1007/s00259-013-2595-4. Epub 2013 Nov 7. Eur J Nucl Med Mol Imaging. 2014. PMID: 24196916
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, Fumoleau P, Brunotte F. Humbert O, et al. Among authors: brunotte f. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27. doi: 10.1007/s00259-013-2616-3. Epub 2013 Nov 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 24258007
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F. Humbert O, et al. Among authors: brunotte f. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1. Epub 2014 Mar 20. Eur J Nucl Med Mol Imaging. 2014. PMID: 24647576
186 results